501 related articles for article (PubMed ID: 24401124)
21. Can low-dose combination products for inhalation be formulated in single crystalline particles?
Kumon M; Kwok PC; Adi H; Heng D; Chan HK
Eur J Pharm Sci; 2010 Apr; 40(1):16-24. PubMed ID: 20172026
[TBL] [Abstract][Full Text] [Related]
22. Inhaled powder formulation of naked siRNA using spray drying technology with l-leucine as dispersion enhancer.
Chow MYT; Qiu Y; Lo FFK; Lin HHS; Chan HK; Kwok PCL; Lam JKW
Int J Pharm; 2017 Sep; 530(1-2):40-52. PubMed ID: 28720537
[TBL] [Abstract][Full Text] [Related]
23. Aerosolization properties, surface composition and physical state of spray-dried protein powders.
Bosquillon C; Rouxhet PG; Ahimou F; Simon D; Culot C; Préat V; Vanbever R
J Control Release; 2004 Oct; 99(3):357-67. PubMed ID: 15451594
[TBL] [Abstract][Full Text] [Related]
24. Development of drug alone and carrier-based GLP-1 dry powder inhaler formulations.
Babenko M; Alany RG; Calabrese G; Kaialy W; ElShaer A
Int J Pharm; 2022 Apr; 617():121601. PubMed ID: 35181460
[TBL] [Abstract][Full Text] [Related]
25. Agglomerated novel spray-dried lactose-leucine tailored as a carrier to enhance the aerosolization performance of salbutamol sulfate from DPI formulations.
Molina C; Kaialy W; Chen Q; Commandeur D; Nokhodchi A
Drug Deliv Transl Res; 2018 Dec; 8(6):1769-1780. PubMed ID: 29260462
[TBL] [Abstract][Full Text] [Related]
26. Particle size dependence of polymorphism in spray-dried mannitol.
Lee YY; Wu JX; Yang M; Young PM; van den Berg F; Rantanen J
Eur J Pharm Sci; 2011 Sep; 44(1-2):41-8. PubMed ID: 21699976
[TBL] [Abstract][Full Text] [Related]
27. Spray dried mannitol carrier particles with tailored surface properties--the influence of carrier surface roughness and shape.
Littringer EM; Mescher A; Schroettner H; Achelis L; Walzel P; Urbanetz NA
Eur J Pharm Biopharm; 2012 Sep; 82(1):194-204. PubMed ID: 22595133
[TBL] [Abstract][Full Text] [Related]
28. Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients.
Razavi Rohani SS; Abnous K; Tafaghodi M
Int J Pharm; 2014 Apr; 465(1-2):464-78. PubMed ID: 24560646
[TBL] [Abstract][Full Text] [Related]
29. [Stability testing of meloxicam-containing microcomposites for inhalation].
Pomázi A; Ambrus R; Szabóné Révész P
Acta Pharm Hung; 2014; 84(2):55-62. PubMed ID: 25167700
[TBL] [Abstract][Full Text] [Related]
30. Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery.
Sinsuebpol C; Chatchawalsaisin J; Kulvanich P
Drug Des Devel Ther; 2013; 7():861-73. PubMed ID: 24039397
[TBL] [Abstract][Full Text] [Related]
31. Freeze-dried mannitol for superior pulmonary drug delivery via dry powder inhaler.
Kaialy W; Nokhodchi A
Pharm Res; 2013 Feb; 30(2):458-77. PubMed ID: 23070603
[TBL] [Abstract][Full Text] [Related]
32. Pulmonary delivery of Nanocomposite Microparticles (NCMPs) incorporating miR-146a for treatment of COPD.
Mohamed A; Pekoz AY; Ross K; Hutcheon GA; Saleem IY
Int J Pharm; 2019 Oct; 569():118524. PubMed ID: 31319144
[TBL] [Abstract][Full Text] [Related]
33. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
[TBL] [Abstract][Full Text] [Related]
34. Characterization of a new inhalable thymopentin formulation.
Wang L; Zhang Y; Tang X
Int J Pharm; 2009 Jun; 375(1-2):1-7. PubMed ID: 19443146
[TBL] [Abstract][Full Text] [Related]
35. The effect of vehicle on physical properties and aerosolisation behaviour of disodium cromoglycate microparticles spray dried alone or with L-leucine.
Najafabadi AR; Gilani K; Barghi M; Rafiee-Tehrani M
Int J Pharm; 2004 Nov; 285(1-2):97-108. PubMed ID: 15488683
[TBL] [Abstract][Full Text] [Related]
36. Investigation of the Changes in Aerosolization Behavior Between the Jet-Milled and Spray-Dried Colistin Powders Through Surface Energy Characterization.
Jong T; Li J; Morton DA; Zhou QT; Larson I
J Pharm Sci; 2016 Mar; 105(3):1156-63. PubMed ID: 26886330
[TBL] [Abstract][Full Text] [Related]
37. Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis.
Momin MAM; Sinha S; Tucker IG; Das SC
Drug Dev Ind Pharm; 2019 Aug; 45(8):1321-1331. PubMed ID: 31014129
[TBL] [Abstract][Full Text] [Related]
38. Development and evaluation of a dry powder formulation of liposome-encapsulated oseltamivir phosphate for inhalation.
Tang Y; Zhang H; Lu X; Jiang L; Xi X; Liu J; Zhu J
Drug Deliv; 2015; 22(5):608-18. PubMed ID: 24299495
[TBL] [Abstract][Full Text] [Related]
39. Excipient-free nanoporous microparticles of budesonide for pulmonary delivery.
Nolan LM; Tajber L; McDonald BF; Barham AS; Corrigan OI; Healy AM
Eur J Pharm Sci; 2009 Jul; 37(5):593-602. PubMed ID: 19463948
[TBL] [Abstract][Full Text] [Related]
40. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
